Oral GLP-1s Explained: Foundayo (Orforglipron), the Wegovy Pill, and What’s Next

There are now two FDA-approved weight-loss pills in the GLP-1 family: the Wegovy pill (semaglutide, from Novo Nordisk), approved in December 2025, and Foundayo (orforglipron, from Eli Lilly), approved in April 2026.

Both are once-a-day tablets that act on the same appetite hormone as the weekly shots. GLP-1 is a hormone your gut releases after you eat, and it tells your brain you’re full.

The two pills are very different, though. The Wegovy pill contains the same peptide as the Wegovy shot (a peptide is a short chain of amino acids, the building blocks of protein), and it has to be taken on an empty stomach.

Foundayo isn’t a peptide at all. It’s a small molecule, meaning a compact, chemically made drug like most pills, and you can take it with or without food.

Below we cover how each pill works, how they compare with each other and with the shots, what they cost, where you can actually get them, and what’s coming next.

The short answer

Foundayo (orforglipron) is FDA-approved for weight management in adults with obesity, or overweight with at least one weight-related condition, as of October 2026. The Wegovy pill (semaglutide tablets) is FDA-approved for chronic weight management and to lower the risk of major heart events in adults with heart disease and obesity or overweight, as of October 2026.

Foundayo also got through the FDA unusually fast. According to the FDA, the agency made its decision 50 days after Lilly filed. It was the first brand-new drug approved under the Commissioner’s National Priority Voucher program, a fast-track program the FDA launched in 2025. For how the rest of the drug class fits together, see our GLP-1 weight-loss hub.

Why GLP-1s were shots until now

Most GLP-1 drugs are peptides. Your stomach is built to break peptides down, since that’s how it digests protein. So if you swallow a peptide drug, very little of it survives the trip to your bloodstream. Even with modern absorption tricks, the Wegovy tablets label estimates that only about 1% to 2% of the semaglutide in a tablet reaches the blood. That’s the main reason semaglutide and tirzepatide started out as injections. (New to the term? Our guide to what peptides are covers the basics.)

Semaglutide pills solve this with a helper ingredient called SNAC, which helps the drug get absorbed through the stomach wall. The helper only works well when the stomach is nearly empty. That’s why the Wegovy pill’s label says to take it first thing in the morning with no more than 4 ounces of plain water. You then wait at least 30 minutes before you eat, drink anything else, or take other pills.

A common argument for pills is that many people won’t use an injection at all, so pills could widen who gets treated. There’s real survey support for the first half of that. In a 2023 KFF poll, 44% of US adults said they’d be interested in a safe, effective weight-loss drug taken as a pill, vs. 23% if it meant giving themselves a weekly shot. What people say in a poll isn’t what they do at the pharmacy, though. We found no data yet on whether pills are actually bringing in people who’d never have started a shot.

Is orforglipron a peptide? No, and here’s why that matters

Orforglipron is not a peptide. The NEJM paper reporting its main trial calls it an “oral small-molecule GLP-1 receptor agonist.” In plain terms, it’s a chemically made pill that switches on the same “I’m full” signal that GLP-1 does. Because it isn’t a protein chain, the stomach doesn’t break it down the way it breaks down semaglutide.

That difference has three practical consequences:

1. No food or water rules. The Foundayo label says it can be taken with or without food. This is a real advantage in daily life, not marketing.
2. It may be easier to make in large amounts. Small molecules are generally simpler to produce at scale than peptides, according to GoodRx’s clinician resource, which is written by a pharmacist and reviewed by a physician. Treat that as an informed view, not something regulators or trials have confirmed.
3. It may affect price over time. Cheaper production may help keep prices down. That’s a possibility, not a promise. Current prices are covered in the cost section below.

One caution if you read the trial papers. The doses tested in Foundayo’s trials and the strengths printed on Foundayo’s label are on different scales, so the numbers don’t line up. Don’t try to match a trial result to a pill strength. Ask your prescriber what applies to you.

Foundayo vs. the Wegovy pill, side by side

No trial has compared these two pills directly for weight loss in people without diabetes. The numbers below come from two separate trials with different people, different lengths, and different designs. Use them for context, not as a scoreboard.

Lilly has also reported a weight-loss figure of up to 12.4% for Foundayo. That number counts only the people who kept taking the drug, which is why it’s higher than the 11.2% in the table.

There is one head-to-head comparison, but it was done in a different group of people. In ACHIEVE-3, Lilly reported that in people with type 2 diabetes, Foundayo led to 6.7% and 9.2% weight loss over 52 weeks, compared with 3.7% and 5.3% for oral semaglutide. It also lowered A1C (a blood test showing your average blood sugar over the past few months) by 1.9% and 2.2%, vs. 1.1% and 1.4%. Lilly makes Foundayo and funded the trial, but this isn’t just a company claim: the full results were peer-reviewed and published in The Lancet in February 2026. The same paper found more people quit Foundayo because of side effects (about 9% to 10%) than quit oral semaglutide (about 5%), per Pharmacy Times’ report on the paper.

The oral semaglutide in that trial was given at the diabetes doses, which are lower than the Wegovy pill’s — a limit University of Glasgow cardiometabolic professor Naveed Sattar, who has consulted for both Lilly and Novo Nordisk, also flagged, calling that dose “relatively modest”. So it’s a solid head-to-head result, but it doesn’t tell you how Foundayo compares with the Wegovy pill for weight loss.

That leaves a genuine trade-off. Foundayo is easier to fit into your day. The Wegovy pill produced more weight loss in its trial and carries an approved heart-protection use.

One more point to avoid mix-ups: the Wegovy pill is not the same product as Rybelsus or Ozempic tablets, which are semaglutide pills approved for type 2 diabetes. Our Wegovy vs. Ozempic guide breaks down every semaglutide pill and shot.

Do the pills work as well as the shots?

It depends on which pill. The Wegovy pill roughly matches the Wegovy shot. Foundayo trails the strongest shots.

The Wegovy pill’s OASIS 4 result (about 14% vs. 2% at 64 weeks; Novo-funded) lands close to the Wegovy shot’s STEP 1 result of 14.9% vs. 2.4% at 68 weeks. Those were separate trials, but the old belief that “pills are always weaker” doesn’t hold here.

Foundayo’s best average result in ATTAIN-1 was 11.2% at 72 weeks, vs. 2.1% on placebo. That’s below tirzepatide, the active ingredient in Zepbound, which produced up to 20.9% average weight loss vs. 3.1% on placebo over the same 72 weeks in its main obesity trial, SURMOUNT-1. Both of those figures count everyone who started the drug, including people who stopped, so it’s a fair like-for-like gap — though they’re still separate trials. Our semaglutide vs. tirzepatide comparison and tirzepatide guide go deeper on the shots.

There’s an interesting twist. A pill might help people keep weight off after a shot. In ATTAIN-MAINTAIN, 376 adults who had already lost weight on semaglutide (Wegovy) or tirzepatide (Zepbound) shots in an earlier trial switched to orforglipron or a placebo for 52 weeks. The results were peer-reviewed and published in Nature Medicine in May 2026. People coming from semaglutide kept about 79% of their earlier weight loss on orforglipron, vs. about 38% on placebo. People coming from tirzepatide kept about 75%, vs. about 49% on placebo.

That’s a real, placebo-controlled signal, not just a press release. But Lilly funded and helped run and write up the trial, it lasted one year, it had no group that simply stayed on their shot, and its doses are on a different scale from the label’s. It isn’t a guide to switching. Any switch from a shot to a pill is a decision for you and your prescriber.

Side effects and who shouldn’t take them

Gut problems are the most common side effects for both pills. In OASIS 4, 74% of people on the Wegovy pill reported gut side effects, compared with 42% on placebo, per the ACC summary. The Foundayo label lists reactions seen in at least 5% of people: nausea, constipation, diarrhea, vomiting, indigestion, belly pain, headache, bloating, fatigue, burping, reflux, gas, and hair loss.

The Wegovy tablets label adds one less familiar effect, dysesthesia. That means unusual skin sensations like tingling, and it was reported by 4.9% of people on the pill vs. 0% on placebo.

Is Foundayo harder to tolerate? Against placebo, its numbers sit in the same range as the Wegovy shot’s, not better. About 8% of people stopped because of side effects vs. 3% on placebo, rising to 10% at the highest dose, per the label. In the Wegovy shot’s weight-loss trials, 6.8% stopped vs. 3.2% on placebo, per the Wegovy label. The Wegovy pill’s gap was smaller in its trial: 7% vs. 6% in OASIS 4. And in the one head-to-head trial, ACHIEVE-3 in type 2 diabetes, more people stopped Foundayo for side effects than stopped the lower-dose oral semaglutide, as covered above. For how this compares with the shots, see our tirzepatide side effects guide.

Both labels carry the same boxed warning. Thyroid C-cell tumors (a type of thyroid tumor) were seen in rodent studies, and it isn’t known whether that applies to people. Neither pill is for anyone with a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer, or of MEN 2, an inherited condition that causes tumors in hormone glands (Foundayo label; Wegovy tablets label). Neither should be combined with another GLP-1 drug.

What they cost and where you actually get them

Both companies sell their pills directly at a published self-pay price, and both start at $149 a month. You still need a prescription either way.

Manufacturer self-pay prices (verified October 20, 2026)

NovoCare says self-pay spending doesn’t count toward your insurance deductible. Both companies can change or cancel these offers. Insurance and Medicare coverage for GLP-1s is its own topic, and our Wegovy vs. Ozempic guide covers it.

Here’s who actually sells these pills, and what each channel does and doesn’t guarantee:

• A prescription filled at a licensed pharmacy. You get the FDA-approved product, made under FDA-inspected manufacturing, with the strength on the label verified, and a prescriber and pharmacist who are accountable. It doesn’t guarantee insurance coverage.
• Manufacturer self-pay (LillyDirect for Foundayo, NovoCare Pharmacy for the Wegovy pill). You get the same branded product at a fixed, published price. A prescription is still required, and the price can change.
• Telehealth that prescribes the brand. Lilly launched Foundayo through telehealth partners as well as LillyDirect. That’s a real prescription filled with the branded drug. Not every telehealth site prescribes the brand, so ask exactly which product you’ll get.
• Compounding pharmacies. As of October 2026, we found no FDA record of orforglipron or semaglutide in any of the categories the FDA uses for ingredients compounding pharmacies may work with. The FDA’s page on unapproved GLP-1 drugs doesn’t mention orforglipron either. Put simply, orforglipron is an FDA-approved drug with no FDA-recognized compounding route on record. A “compounded” version of either pill would not be FDA-reviewed. Our explainer on compounding-eligible vs. FDA-approved explains the difference.
• “Research use only” websites. In a search-results scan in October 2026, we found at least one consumer-facing “research use only” site listing orforglipron as capsules. It carried a “not for human use” disclaimer. These sites sell directly to consumers with no prescription and no medical oversight. Some research-use sellers publish a third-party lab certificate for a batch. A certificate like that covers one batch, isn’t checked by any regulator, and doesn’t make the product legal for human use. With pills, sterility isn’t the main concern, as it is with injectable vials. The real unknowns are whether the capsule contains what the label says, and how much of it.

One fact is worth stating plainly: at the lowest strength, the branded pills now cost $149 a month through the manufacturers. So low price is no longer an obvious reason to turn to the gray market for these drugs, the way it has been for some injectables. Being able to buy something online tells you nothing about whether it’s safe or legal. For changes to any of these statuses, follow our regulatory tracker.

What’s next: the oral pipeline

Everything in this section is investigational, meaning not approved and still in trials.

• Foundayo for type 2 diabetes. Lilly said in June 2026 that it planned to file for a diabetes approval by the end of the second quarter of 2026. As of October 20, 2026, Drugs@FDA shows no diabetes approval.
• Aleniglipron (Structure Therapeutics). This is another small-molecule GLP-1 pill. The company reported about 16% weight loss beyond placebo at 44 weeks in its mid-stage trial, and said it expected to start its large final-stage trials in the third quarter of 2026. These results are company-reported.
• Oral amycretin (Novo Nordisk). This single molecule acts on GLP-1 and on amylin, a second fullness hormone. In June 2025, Novo said it planned to move both the pill and shot versions into final-stage weight-loss trials starting in early 2026.
• Oral VK2735 (Viking Therapeutics). This is a pill that targets GLP-1 and a second gut hormone, GIP, the same pair tirzepatide targets. In a 13-week trial, Viking reported up to 12.2% average weight loss vs. 1.3% on placebo. But 28% of people on the drug stopped treatment, compared with 18% on placebo, and gut side effects were the most common reason.

For the injectable drugs in the pipeline, see our retatrutide guide. For the full semaglutide brand picture, see our semaglutide guide.

Key sources

1. U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program (April 1, 2026).
2. Drugs@FDA. NDA 220934 — Foundayo (orforglipron).
3. FDALabel. Foundayo prescribing information (rev. July 29, 2026).
4. Drugs@FDA. NDA 218316 — Wegovy tablets; Wegovy tablets prescribing information.
5. Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025. doi:10.1056/NEJMoa2511774.
6. Wharton S, et al. Oral semaglutide in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393:1077-1087. doi:10.1056/NEJMoa2500969.
7. Rosenstock J, et al. Orforglipron vs. oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026. doi:10.1016/S0140-6736(26)00202-3. Trial registry: NCT06045221.
8. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of October 1, 2026).
9. Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. doi:10.1038/s41591-026-04386-7.

FAQs about orforglipron